Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

October 13, 2026 9:44 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $40.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found